Business Context and Reporting Period
This Form 8-K Current Report was filed by Arvinas, Inc. on December 14, 2020. The filing serves as a Regulation FD disclosure regarding significant clinical program updates for the Company's lead PROTAC® protein degrader candidates, ARV-471 (for ER+/HER2- breast cancer) and ARV-110 (for metastatic castrate-resistant prostate cancer). The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: This filing is a current report focused on clinical developments and does not contain financial statements, revenue figures, profit data, cash flow metrics, or debt information. The text does not provide a clear value for any financial metric.
Material Changes and Clinical Updates
ARV-471 (Breast Cancer)
- Study Status: Interim data from the dose escalation portion of the Phase 1/2 trial in patients with locally advanced or metastatic ER+/HER2- breast cancer.
- Efficacy: As of November 11, 2020, 21 patients were dosed. One patient achieved a confirmed partial response (51% tumor reduction). The Clinical Benefit Rate (CBR) was 42% (5 of 12 evaluable patients).
- Safety: Well tolerated with no Grade 3 or 4 treatment-related adverse events. Most common events were nausea (24%), arthralgia (19%), and fatigue (19%). No dose-limiting toxicities reported.
- Mechanism: Tumor biopsies showed ER degradation up to 90% (average 62%) at doses up to 120 mg.
ARV-110 (Prostate Cancer)
- Study Status: Interim data from the dose escalation portion of the Phase 1/2 trial in men with metastatic castrate-resistant prostate cancer (mCRPC).
- Efficacy: PSA50 responses (≥50% reduction in prostate-specific antigen) observed at doses >280 mg. In patients with exposures above the predicted efficacy threshold, 14% (4 of 28) achieved PSA50 response.
- Subgroup Analysis: Strong response in molecularly defined populations: 40% (2 of 5) of patients with T878 or H875 AR mutations achieved PSA50 response. 13% (2 of 15) of wild-type AR patients also responded.
- Population: Highly pretreated cohort; 76% had prior chemotherapy, 82% had prior abiraterone and enzalutamide.
Guidance, Outlook, and Risks
Future Milestones and Outlook
- ARV-471: Dose escalation expected to complete in H1 2021; dose expansion to follow. Phase 1b combination trial with palbociclib (Ibrance®) to initiate in December 2020. Two additional studies planned for H2 2021.
- ARV-110: ARDENT Phase 2 expansion initiated in October 2020 with subgroups for T878/H875 mutations and less-pretreated patients. Complete dose escalation data expected in 2021; interim expansion data in H2 2021.
- Pipeline: IND application for ARV-766 (AR degrader) expected in H1 2021. INDs for BCL6, tau, and an undisclosed oncology program anticipated in 2022.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks include the uncertainty of clinical trial results, the ability to complete trials on expected timelines, and the sufficiency of cash resources to fund operations. The Company notes that actual results may differ materially from expectations due to various uncertainties.
Investor Verification Checklist
- Verify the specific patient numbers and response rates for ARV-471 and ARV-110 in the attached press release (Exhibit 99.1) and presentation (Exhibit 99.2).
- Confirm the timeline for the initiation of the ARV-471 combination trial with palbociclib and the ARV-110 Phase 2 expansion subgroups.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Monitor upcoming data readouts scheduled for 2021 regarding dose escalation completion and Phase 2 expansion interim data.
- Assess the regulatory implications of the molecularly defined response rates (T878/H875 mutations) for ARV-110.